Provided by Tiger Trade Technology Pte. Ltd.

Global Partners LP

50.87
+0.10500.21%
Volume:33.96K
Turnover:1.73M
Market Cap:1.73B
PE:10.41
High:51.36
Open:50.69
Low:50.12
Close:50.76
52wk High:54.29
52wk Low:39.58
Shares:34.00M
Float Shares:27.67M
Volume Ratio:0.53
T/O Rate:0.12%
Dividend:3.06
Dividend Rate:6.01%
EPS(TTM):4.89
EPS(LYR):2.11
ROE:27.21%
ROA:5.25%
PB:2.58
PE(LYR):24.11

Loading ...

Earnings Flash (GLP) Global Partners Posts Q1 Net Income $1.85 per Unit, vs. FactSet Est of $0.33

MT Newswires Live
·
May 08

Global Partners Q1 FY26 net income more than tripled to $70.1 million; net sales rise 15.9% to $5.3 billion

Reuters
·
May 08

Global Partners Lp Q1 Operating Income USD 105.739 Million

THOMSON REUTERS
·
May 08

Voyager Reports First Quarter 2026 Financial and Operating Results

GlobeNewswire
·
May 08

Wegovy pill saw the fastest take-up since the advent of GLP-1 drugs

Dow Jones
·
May 06

Editas Medicine Announces First Quarter 2026 Results and Business Updates

GlobeNewswire
·
May 05

Does Global Partners' (GLP) Steady Distribution Reveal Enduring Value Or Mask Shifting Risks?

Simply Wall St.
·
May 04

Structure Therapeutics (GPCR) Is Down 7.2% After Strong Phase 2 Oral GLP‑1 Obesity Data – Has The Bull Case Changed?

Simply Wall St.
·
May 03

Can GLP-1s curb alcohol use? A new study says the drugs can reduce heavy drinking.

Dow Jones
·
May 01

Earning Preview: Global Partners LP this quarter’s revenue is expected to increase by 23.69%, and institutional views are mixed

Earnings Agent
·
May 01

Press Release: Global Partners Declares First-Quarter 2026 Cash Distribution of $0.7650 on Common Units

Dow Jones
·
Apr 30

Loblaw Earns Buy Rating on Strong Earnings Momentum, Market Share Gains and GLP‑1 Growth Tailwinds

TIPRANKS
·
Apr 30

Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer’s Disease

GlobeNewswire
·
Apr 28

A Look At Insulet (PODD) Valuation After Device Correction And Growing GLP-1 Competition Concerns

Simply Wall St.
·
Apr 28

ASCLETIS-B Completes Patient Enrollment for US Phase II Trial of Oral GLP-1R Agonist ASC30 in Diabetes

Stock News
·
Apr 27

Ascletis Completes Enrollment in U.S. Phase II Study of ASC30, an Oral Small Molecule GLP-1R Agonist, for the Treatment of Diabetes

prnewswire
·
Apr 27

Wedding Dresses Now Come With a Legal Waiver for Brides on GLP-1s -- WSJ

Dow Jones
·
Apr 25

Is It Time To Reassess Global Partners (GLP) After Recent Energy Sector Coverage?

Simply Wall St.
·
Apr 25

Global Partners schedules first-quarter results conference call

Reuters
·
Apr 24

Domestic Long-Acting GLP-1 Drug Tops 100 Million Yuan in First-Year Sales but Faces Deepening Losses

Deep News
·
Apr 24